Safety and immunogenicity of SII-NVX-CoV2373 (COVID-19 vaccine) in adults in a phase 2/3, observer-blind, randomised, controlled study-Reference-Cited by-同舟云学术

Safety and immunogenicity of SII-NVX-CoV2373 (COVID-19 vaccine) in adults in a phase 2/3, observer-blind, randomised, controlled study

Published:2023-03 Issue: Volume:10 Page:100139
ISSN:2772-3682
Container-title:The Lancet Regional Health - Southeast Asia
language:en
Short-container-title:The Lancet Regional Health - Southeast Asia

Author:

Kulkarni Prasad S.,Kadam Abhijit,Godbole Sheela,Bhatt Varsha^ORCID,Raut Abhishek^ORCID,Kohli Sunil,Tripathi Santanu,Kulkarni Praveen,Ludam Rakhi,Prabhu Madhav,Bavdekar Ashish,Gogtay Nithya J.,Meshram Sushant,Kadhiravan Tamilarasu,Kar Sonali^ORCID,Narayana D.H. Ashwath,Samuel Clarence,Kulkarni Govind,Gaidhane Abhay^ORCID,Sathyapalan Dipu^ORCID,Raut Sidram,Hadda Vijay,Bhalla Hira Lal,Bhamare Chetanraj,Dharmadhikari Abhijeet,Plested Joyce S.,Cloney-Clarke Shane,Zhu Mingzhu,Pryor Melinda,Hamilton Stephanie,Thakar Madhuri,Shete Ashwini,Gautam Manish,Gupta Nivedita,Panda Samiran,Shaligram Umesh,Poonawalla Cyrus S.,Bhargava Balram,Gunale Bhagwat,Kapse Dhananjay,Kanitkar Shubhangi A.,Kakrani Arjun L.,Tripathy Srikanth P.,Tilak Abhijit V.,Dhamne Akshay A.,Mirza Shahzad Beg,Athavale Prachi V.,Bhowmik Mandakini,Ratnakar Parag J.,Gupta Subodh,Deotale Vijayshri,Jain Jyoti,Kalantri Ashwini,Jain Vineet,Goyal Nidhi,Arya Alok,Rongsen-Chandola Temsunaro,Dasgupta Shreyasi,Periera Pratibha,A Vanmathi,Kawade Anand,Gondhali Arunkumar,Kudyar Palvi,Singh Abhishek,Yadav Ravi,Alexander Alina,Gunasekaran Venugopalan,Dineshbabu Sekar,Samantaray P.C.,Ravish H.S.,Kamra Deepshikha,Gaidhane Shilpa,Zahiruddin Quazi Syed,Moni Merlin,Kumar Anil,Dravid Ameet,Mohan Anant,Suri Tejas,Patel Tejas K.,Kishore Surekha,Choche Rahul,Ghatage Deepak,Salvi Sugam

Publisher

Elsevier BV

Reference25 articles.

1. Singh I, Patra G. Aerosol transmission of SARS-CoV-2: the unresolved paradox;Priyanka;Travel Med Infect Dis,2020

2. Phase 1-2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine;Keech;N Engl J Med,2020

3. Different dose regimens of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373) in younger and older adults: a phase 2 randomized placebo-controlled trial;Formica;PLoS Med,2021

4. Safety and efficacy of NVX-CoV2373 Covid-19 vaccine;Heath;N Engl J Med,2021

5. Efficacy and safety of NVX-CoV2373 in adults in the United States and Mexico;Dunkle;N Engl J Med,2022

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Phase 3, randomized, non-inferiority study of a heterologous booster dose of SARS CoV-2 recombinant spike protein vaccine in adults;Scientific Reports;2023-10-03

2. Safety and Immunogenicity of SARS-CoV-2 Recombinant Spike Protein Vaccine in Children and Adolescents in India;JAMA Pediatrics;2023-09-01

3. NVX-CoV2373-induced T- and B-cellular immunity in immunosuppressed people with multiple sclerosis that failed to respond to mRNA and viral vector SARS-CoV-2 vaccines;Frontiers in Immunology;2023-07-20

4. Patients under medical conditions, immunogenicity and safety of covid-19 vaccines: a systematic review and meta-analysis;Journal of Lung, Pulmonary & Respiratory Research;2023-03-30

5. A Phase 2/3 observer-blind, randomized, controlled study to determine the safety and immunogenicity of SARS-CoV-2 recombinant spike protein vaccine in Indian children and adolescents aged 2 to 17 years;2023-01-04